Patents Examined by Claire Kaufman
  • Treatment of cancer with dual targeting of CD47 and EGFR
    Patent number: 11130813
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 28, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
  • EGFR-binding agents and uses thereof
    Patent number: 11124575
    Abstract: An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: September 21, 2021
    Assignees: University of Saskatchewan, The Governing Council of the University of Toronto
    Inventors: Sachdev Sidhu, Shane Miersch, Clarence Ronald Geyer
  • Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms
    Patent number: 11117973
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF) and methods of treatment. More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 14, 2021
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
    Patent number: 11111284
    Abstract: The invention features homo-multimers, e.g., homo-trimers, of TNFSF or TNF-like ligand muteins in which each TNFSF ligand or TNF-like ligand mutein monomer contains at least one cysteine residue substitution or insertion that promotes the formation of a disulfide bond with a cysteine residue on a neighboring TNFSF or TNF-like ligand mutein monomer. The invention features methods of producing such TNFSF and TNF-like ligand muteins, pharmaceutical compositions containing such muteins, and methods of using such muteins in cancer immunotherapy, in treating autoimmune and neurological diseases, and in reducing or eliminating the complications and risks of rejection in organ transplantation or tissue or organ repair or regeneration.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: September 7, 2021
    Assignee: The General Hospital Corporation
    Inventors: Denise L. Faustman, Eva Vanamee
  • Compositions for achieving therapeutically effective doses of anti-CD47 agents
    Patent number: 11104731
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: August 31, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • Compositions and methods for treating pancreatitis and pain with death receptor agonists
    Patent number: 11084879
    Abstract: Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 10, 2021
    Assignee: The Johns Hopkins University
    Inventors: Seulki Lee, Martin G. Pomper, Ogyi Park, Magdalena Scully, Pankaj J. Pasricha
  • Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
    Patent number: 11071780
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 27, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. Vitti, Kristine A. Erickson, Karen W. Chu, Stanley J. Wiegand, Jingtai Cao, Ivan B. Lobov, Saurabh Wadhwa, Kenneth S. Graham, Daniel Dix
  • Frizzled-4 mutation indicator of retinopathy and intrauterine growth restriction
    Patent number: 11041863
    Abstract: A method for determining the necessity of a pre-term birth treatment is provided based on obtaining a biological sample from a subject. The biological sample is analyzed for the presence of (P33S;P168S) Frizzled4 (Fzd4) gene variation. The subject or a fetus thereof is then treated for a proclivity to pre-term birth. The Fzd4 protein itself can also be analyzed for the (P33S;P168S) Fzd4 mutation.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: June 22, 2021
    Assignee: RETINAL SOLUTIONS LLC
    Inventors: Kimberly Drenser, Michael T. Trese, Antonio Capone
  • Ameliorating systemic sclerosis with death receptor agonists
    Patent number: 11007251
    Abstract: The present disclosure relates to methods and compositions for treating and/or preventing autoimmune fibrosis, such as systemic sclerosis (SSc; scleroderma). The method includes administering to a subject in need thereof an effective amount of a death receptor agonist. Suitable death receptor agonists include tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), agonistic death receptor antibodies, and variants, analogues, or derivatives thereof. The administration of the death receptor agonist blocks fibroblast or profibrogenic cell activation, and/or reduces or depletes myofibroblasts, thereby reducing or preventing systemic sclerosis.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 18, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Seulki Lee, Martin G. Pomper, Jong-Sung Park, Yumin Oh, Magdalena Scully, Maureen Horton
  • Agents for use in the therapeutic treatment of hyperopia
    Patent number: 11008385
    Abstract: The present invention relates to agents for use in the prophylactic or therapeutic treatment of myopia in a subject, wherein said agents are capable of decreasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject in a direct or indirect manner. The present invention further relates to agents for use in the prophylactic or therapeutic treatment of hyperopia in a subject, wherein said agents are capable of increasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: May 18, 2021
    Inventors: Shefali Brinda Jonas, Rahul Arvo Jonas, Jost B. Jonas, Songhomitra Panda-Jonas
  • Nucleic acids encoding binding members to TNF alpha
    Patent number: 10995138
    Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 4, 2021
    Assignee: Cell Medica Inc.
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar
  • Use of a VEGF antagonist to treat angiogenic eye disorders
    Patent number: 10973879
    Abstract: The present invention provides methods for treating or preventing diabetic retinopathy, e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of a 2 mg aflibercept by intravitreal injection q8 weeks after three or five initial monthly doses (2q8) or 2 mg q16 weeks after three initial monthly doses and one 8-week interval (2q16). Moreover, the present invention provides methods for reversing or halting the progression NPDR to PDR (e.g., such that the DRSS is reduced by 2 or 3 levels) or preventing the occurrence or reoccurrence of a vision threatening complication by administering aflibercept according to the dosing regimens set forth herein.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 13, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. Vitti, Alyson J. Berliner, Karen Chu
  • TL1A antibodies and uses thereof
    Patent number: 10968279
    Abstract: Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Achal Pashine, Guodong Chen
  • Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
    Patent number: 10967005
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 6, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Highly potent antibodies binding to death receptor 4
    Patent number: 10941204
    Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: March 9, 2021
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
  • sDR5-Fc fusion protein mutant and use thereof
    Patent number: 10918739
    Abstract: The present disclosure discloses a human sDR5-Fc fusion protein in the preparation of adjuvant therapy for myocardial ischemia-reperfusion injury. The sDR5-Fc antibody fusion protein of the disclosure is prepared by connecting the 182 amino acids in DR5 extracellular domain with the human anti-Fc fragments. It has been tested that the sDR5-Fc antibody fusion protein of the disclosure can basically avoid Fc-mediated ADCC effect and can significantly reduce the area of myocardial infarction in rats of myocardial ischemia-reperfusion models.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: February 16, 2021
    Assignee: Suzhou Yongxin Biological Science and Technology Co., Ltd
    Inventor: Yuanfang Ma
  • Pharmaceutical formulation comprising anti-EGFR antibody
    Patent number: 10918717
    Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: February 16, 2021
    Assignee: GREEN CROSS CORPORATION
    Inventors: Yong Woon Choi, Yoo Hoon Kim, Jungsub Choi
  • Anti-RANKL antibodies and uses thereof
    Patent number: 10913799
    Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: February 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, Victor H Obungu
  • Anti-CD137 antibodies
    Patent number: 10906983
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and is useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 2, 2021
    Assignee: ELI LILLY AND COMPANY
    Inventors: Christopher Carl Frye, Michael Dewain Kalos, Helen Kotanides, Stephanie Lynn Sandefur
  • Antagonistic anti-tumor necrosis factor receptor 2 antibodies
    Patent number: 10906982
    Abstract: Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 2, 2021
    Assignee: The General Hospital Corporation
    Inventor: Denise L. Faustman